Neil Cashman

Neil Cashman

Company: ProMIS Neurosciences

Job title: Chief Scientific Officer & Co-Founder


Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distraction 3:00 pm

Exploring aggregated Abeta (fibrils and oligomers, not monomers) is the target of many emerging antibodies and other therapeutics Investigating oligomeric Abeta as the appropriate molecular species for therapeutic activity without adverse effects (e.g., ARIA) Understanding why PMN310 from ProMIS is specific for Abeta oligomers, without target distraction from monomers or fibrilsRead more

day: Track A - Day 1 PM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.